These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34116955)

  • 1. Intravesical Bacillus Calmette-Guérin Treatment Is Inversely Associated With the Risk of Developing Alzheimer Disease or Other Dementia Among Patients With Non-muscle-invasive Bladder Cancer.
    Kim JI; Zhu D; Barry E; Kovac E; Aboumohamed A; Agalliu I; Sankin A
    Clin Genitourin Cancer; 2021 Dec; 19(6):e409-e416. PubMed ID: 34116955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
    Wang E; Hagberg O; Malmström PU
    PLoS One; 2023; 18(12):e0292174. PubMed ID: 38096211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
    Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
    BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
    Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
    Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.
    Lee S; Lim B; You D; Hong B; Hong JH; Kim CS; Ahn H; Jeong IG
    Urol Oncol; 2020 Nov; 38(11):851.e11-851.e17. PubMed ID: 32800440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial.
    Ansari Djafari A; Javanmard B; Razzaghi M; Hojjati SA; Razzaghi Z; Faraji S; Rahavian A; Garoosi M
    Urol J; 2023 Feb; 20(2):123-128. PubMed ID: 35689462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
    Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
    PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non-Muscle-Invasive Bladder Cancer.
    Weinberg MS; Zafar A; Magdamo C; Chung SY; Chou WH; Nayan M; Deodhar M; Frendl DM; Feldman AS; Faustman DL; Arnold SE; Vakulenko-Lagun B; Das S
    JAMA Netw Open; 2023 May; 6(5):e2314336. PubMed ID: 37204792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer's disease in bladder cancer patients.
    Gofrit ON; Klein BY; Cohen IR; Ben-Hur T; Greenblatt CL; Bercovier H
    PLoS One; 2019; 14(11):e0224433. PubMed ID: 31697701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
    Taoka R; Kobayashi T; Hidaka Y; Abe H; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Kamiyama M; Morita S; Ogawa O; Nishiyama H; Kitamura H; Sugimoto M;
    Urol Oncol; 2022 Mar; 40(3):107.e1-107.e9. PubMed ID: 34454824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Immune-inflammation Index (SII) During Induction has Higher Predictive Value Than Preoperative SII in Non-muscle-invasive Bladder Cancer Patients Receiving Intravesical Bacillus Calmette -Guerin.
    Deng-Xiong L; Qing-Xin Y; De-Chao F; Fa-Cai Z; Rui-Cheng W; Shi X; Han P
    Clin Genitourin Cancer; 2023 Jun; 21(3):e145-e152. PubMed ID: 36503724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA; Zhu F; Herr HW
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
    Lawler C; Gu L; Howard LE; Branche B; Wiggins E; Srinivasan A; Foster ML; Klaassen Z; De Hoedt AM; Gingrich JR; Theodorescu D; Freedland SJ; Williams SB
    Cancer; 2021 Nov; 127(21):3998-4005. PubMed ID: 34237155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Huang Z; Liu H; Wang Y; Zhang C; Xu T
    Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.